, Volume 57, Issue 1, pp 183–186 | Cite as

Memory and Hashimoto’s thyroiditis under levothyroxine treatment: is there a placebo or nocebo effect?

  • Vaitsa GiannouliEmail author
Research Letter


According to numerous studies, chronic autoimmune Hashimoto’s thyroiditis (HT) is the most common reported cause of hypothyroidism, which is considered to have detrimental effects on the brain, and consequently on one of the most important cognitive functions, namely memory; yet some research suggests that treatment of hypothyroidism, resulting in a return to euthyroidism in HT, may be associated with definite recovery of overall neurocognitive functioning [1].

Although healthy euthyroid middle-aged women, with higher levels of free triidothyronine (T3) and thyroglobulin antibodies (Anti-TG) levels, within the normal range, showed slower cognitive performance and more errors on neuropsychological tests of executive function [2], no research has not confirmed that euthyroidism under synthetic levothyroxine (LT4) treatment leads to serious neuropsychological deficits (e.g. in immediate recall, delayed recall, verbal learning, inhibitory efficiency, information processing...



The author would like to thank Jennifer A. McCabe, PhD for her support with the English language editing of the text.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    E.M. Wekking, B.C. Appelhof, E. Fliers, A.H. Schene, J. Huyser, J.G. Tijssen, W.M. Wiersinga, Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur. J. Endocrinol. 153(6), 747–753 (2005)CrossRefGoogle Scholar
  2. 2.
    M. Grigorova, B.B. Sherwin, Thyroid hormones and cognitive functioning in healthy, euthyroid women: a correlational study. Horm. Behav. 61, 617–622 (2012)CrossRefGoogle Scholar
  3. 3.
    V. Giannouli, K.A. Toulis, N. Syrmos, Cognitive function in Hashimoto’s thyroiditis under levothyroxine treatment. Hormones (Athens) 13(3), 430–433 (2014)CrossRefGoogle Scholar
  4. 4.
    A.K. Shapiro, L.A. Morris, The placebo effect in medical and psychological therapies. In In: S.L. Garfield, A.E. Bergin (eds) Handbook of psychotherapy and behavior change , pp. 369–409. Wiley, New York, NY (1978)Google Scholar
  5. 5.
    W. Häuser, E. Hansen, P. Enck, Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch. Arztebl. Int. 109(26), 459–465 (2012)PubMedPubMedCentralGoogle Scholar
  6. 6.
    V. Giannouli, N. Syrmos, Exploring attitudes towards endocrine disease. Endocrine 55(2), 655–657 (2017)CrossRefGoogle Scholar
  7. 7.
    J.B. Hale, J.A.B. Hoeppner, C.A. Fiorello, Analyzing digit span components for assessment of attention processes. J. Psychoeduc. Assess 20(2), 128–143 (2002)CrossRefGoogle Scholar
  8. 8.
    E.N. Rosenthal, C.A. Riccio, K.M. Gsanger, K.P. Jarratt, Digit Span components as predictors of attention problems and executive functioning in children. Arch. Clin. Neuropsychol. 21(2), 131–139 (2006)CrossRefGoogle Scholar
  9. 9.
    M.H. Samuels, Psychiatric and cognitive manifestations of hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 377–383 (2014)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.School of Medicine, Aristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations